secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001213900-25-010085
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO
-------------------------------------------------------------------

- Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.
- Brian Kotzin, MD, appointed interim CMO; he previously served as strategic advisor for rezpegaldesleukin program since April 2023.
- Kotzin has over 40 years immunology experience; was VP at Amgen and held academic positions; will assist search for permanent CMO.
- Kotzin currently serves on boards of Argenx SE, Biora Therapeutics, and Genascence Corporation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025010085/0001213900-25-010085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025010085/ea0229922-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer